Review



fibroblast cell line sto  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    ATCC fibroblast cell line sto
    Fibroblast Cell Line Sto, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 452 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fibroblast cell line sto/product/ATCC
    Average 95 stars, based on 452 article reviews
    fibroblast cell line sto - by Bioz Stars, 2026-05
    95/100 stars

    Images



    Similar Products

    fibroblast cell line sto  (ATCC)
    95
    ATCC fibroblast cell line sto
    Fibroblast Cell Line Sto, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fibroblast cell line sto/product/ATCC
    Average 95 stars, based on 1 article reviews
    fibroblast cell line sto - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    mouse embryonic fibroblast cell line sto feeder cells  (ATCC)
    95
    ATCC mouse embryonic fibroblast cell line sto feeder cells
    Mouse Embryonic Fibroblast Cell Line Sto Feeder Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse embryonic fibroblast cell line sto feeder cells/product/ATCC
    Average 95 stars, based on 1 article reviews
    mouse embryonic fibroblast cell line sto feeder cells - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    murine fibroblast cell line sto  (ATCC)
    95
    ATCC murine fibroblast cell line sto
    Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
    Murine Fibroblast Cell Line Sto, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine fibroblast cell line sto/product/ATCC
    Average 95 stars, based on 1 article reviews
    murine fibroblast cell line sto - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    sto mouse embryonic fibroblast cell line  (ATCC)
    95
    ATCC sto mouse embryonic fibroblast cell line
    Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
    Sto Mouse Embryonic Fibroblast Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sto mouse embryonic fibroblast cell line/product/ATCC
    Average 95 stars, based on 1 article reviews
    sto mouse embryonic fibroblast cell line - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    mouse embryonic fibroblast mef cell line  (ATCC)
    95
    ATCC mouse embryonic fibroblast mef cell line
    Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
    Mouse Embryonic Fibroblast Mef Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse embryonic fibroblast mef cell line/product/ATCC
    Average 95 stars, based on 1 article reviews
    mouse embryonic fibroblast mef cell line - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    mouse embryonic fibroblast cell line sto  (ATCC)
    95
    ATCC mouse embryonic fibroblast cell line sto
    Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
    Mouse Embryonic Fibroblast Cell Line Sto, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse embryonic fibroblast cell line sto/product/ATCC
    Average 95 stars, based on 1 article reviews
    mouse embryonic fibroblast cell line sto - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    mouse embryonic fibroblast cell line called sto cells  (ATCC)
    95
    ATCC mouse embryonic fibroblast cell line called sto cells
    Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
    Mouse Embryonic Fibroblast Cell Line Called Sto Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse embryonic fibroblast cell line called sto cells/product/ATCC
    Average 95 stars, based on 1 article reviews
    mouse embryonic fibroblast cell line called sto cells - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    h4ac blotting derived fr fibroblast cell line  (ATCC)
    95
    ATCC h4ac blotting derived fr fibroblast cell line
    Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
    H4ac Blotting Derived Fr Fibroblast Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/h4ac blotting derived fr fibroblast cell line/product/ATCC
    Average 95 stars, based on 1 article reviews
    h4ac blotting derived fr fibroblast cell line - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    mouse sim thioguanine ouabain resistant mouse fibroblast cell line sto fibroblasts  (ATCC)
    95
    ATCC mouse sim thioguanine ouabain resistant mouse fibroblast cell line sto fibroblasts
    Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + <t>STO</t> <t>fibroblasts</t> expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.
    Mouse Sim Thioguanine Ouabain Resistant Mouse Fibroblast Cell Line Sto Fibroblasts, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse sim thioguanine ouabain resistant mouse fibroblast cell line sto fibroblasts/product/ATCC
    Average 95 stars, based on 1 article reviews
    mouse sim thioguanine ouabain resistant mouse fibroblast cell line sto fibroblasts - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + STO fibroblasts expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.

    Journal: Scientific Reports

    Article Title: The efficacy of an embryonic stem cell-based vaccine for lung cancer prevention depends on the undifferentiated state of the stem cells

    doi: 10.1038/s41598-024-83932-0

    Figure Lengend Snippet: Differentiation of ES-D3 cells decreases their efficacy to prevent the development of implanted lung tumors. ( A ) The schematic depiction of immunization regimen. Male and female C57BL/6 mice were immunized twice with 1 × PBS (vehicle control), parental ES-D3 cells + STO fibroblasts expressing GM-CSF (STO/GM-CSF) or differentiated ES-D3 cells + STO/GM-CSF prior to subcutaneous challenge with LLC cells (0.15 × 10 6 ) at Day 14. Tumor-free mice were challenged again with LLC cells (0.15 × 10 6 ) at day 72. ( B ) The percentages of tumor-free male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender) following the first LLC injection are shown. Log-rank test; Asterisk (*) indicates p < 0.05; Asterisks (**) indicate p < 0.01; Asterisks (***) indicate p < 0.001. ( C ) Kaplan–Meier survival curve demonstrates the probability of survival in male mice (n = 8), female mice (n = 8), or male + female mice (n = 16, 8 mice/gender). Log-rank test; Asterisks (***) indicate p < 0.001. ( D ) Twenty-eight days after the second LLC challenge, the percentages of tumor-bearing mice in mice immunized with parental ES-D3 cells + STO/GM-CSF (n = 8) or differentiated ES-D3 cells + STO/GM-CSF (n = 2) were determined.

    Article Snippet: Murine fibroblast cell line STO (ATCC # CRL-1503) infected with a replication-defective retrovirus expressing murine GM-CSF cDNA was acquired from Dr. Glenn Dranoff (Novartis Institutes for Biomedical Research; Boston, MA).

    Techniques: Control, Expressing, Injection